Phase 1 trial

Design Therapeutics Reports RESTORE-FA Progress and Advances GeneTAC® Pipeline

CARLSBAD, Calif., Aug. 3, 2026 Design Therapeutics, Inc. reported second-quarter 2026 financial results while providing key clinical updates across...

By cGxPwire Editor
August 4, 2026

Bio-Pharma

Verdiva Bio Starts Phase 1 Trial of Weekly Oral VRB-103

LONDON and SAN FRANCISCO, July 30, 2026 Verdiva Bio announced that the first patient has been dosed in a...

By cGxPwire Editor
July 31, 2026

Bio-Pharma

Iksuda Therapeutics Secures FDA IND Clearance for IKS04

Newcastle, UK, July 30, 2026 Iksuda Therapeutics has received U.S. Food and Drug Administration (FDA) Investigational New Drug (IND)...

By cGxPwire Editor
July 30, 2026

Bio-Pharma

Revagenix Doses First Patient in Phase 1 Rev-56 Trial

SAN FRANCISCO, Calif., July 27, 2026 Revagenix, Inc. announced that the first participant has been dosed in the Phase...

By cGxPwire Editor
July 29, 2026

.Clinical

Bambusa Therapeutics Reports Positive Early Phase 1 Results for BBT001 in Atopic Dermatitis

BOSTON, July 27, 2026 Bambusa Therapeutics announced encouraging preliminary proof-of-concept results from its ongoing global Phase 1 clinical trial...

By cGxPwire Editor
July 28, 2026

Find Jobs Across Pharma, Biotech & Life Sciences

Discover verified job opportunities from top companies worldwide. Apply easily and grow your career in the life sciences industry.

Bio-Pharma

Neumora Therapeutics Announces Positive NMRA-215 Toxicology Findings

WATERTOWN, Mass., July 27, 2026 Neumora Therapeutics announced positive preclinical toxicology results for NMRA-215, its investigational brain-penetrant oral NLRP3...